March 19, 2025

Hyloris Announces Alenura® Positive IDMC Results

The Independent Data Monitoring Committee (IDMC) Recommends Continuation of the Alenura Clinical Trial Following Interim Assessment. Read full Press Release.

Stay Connected

More Updates

Vaneltix Starts New Multiple Dose Clinical Trial

December 14, 2024, New Brunswick, NJ – Vaneltix Pharma, Inc. (“Vaneltix” or “the Company”), a specialty pharmaceutical company focused on the development of solutions for

December 14, 2024

Vaneltix planning to enroll subjects in new round of clinical trials

On Tuesday, February 21st 2023, Bound Brook, NJ – Vaneltix Pharma, Inc. (Formerly Urigen Pharmaceuticals, Inc.; “Vaneltix” or “the Company”), a specialty pharmaceutical company focused

February 21, 2023

Vaneltix enters joint development agreement with Hyloris Pharmaceuticals

On Thursday, December 16, Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company (“Hyloris”) with respect to Vaneltix’s Alenura™

December 21, 2021

Vaneltix Pharma, Inc.

317 George St., Ste. 400,
New Brunswick, NJ 08901
United States

This website is created by Blink.